Tesamorelin

What it is?

Tesamorelin is a growth hormone–releasing hormone (GHRH) analogue studied for stimulating the body’s own GH production through receptor-specific activation in the pituitary. It is frequently positioned in research protocols focused on visceral adiposity, metabolic regulation, and lean-mass preservation.

Dripfy Advantage

• Receptor engagement: Binds to GHRH receptors in the pituitary to stimulate endogenous GH release.
• Physiological GH stimulation: Promotes GH production via the native hypothalamic–pituitary axis, supporting a more physiological endocrine activation approach.
• Visceral adipose signalling: Often studied for effects on visceral fat–related endpoints, while maintaining attention to lean-tissue preservation markers.
• Metabolic pathway influence: Associated with improvements in glucose–lipid metabolism markers and body-composition regulation pathways.
• Protocol suitability: Commonly used where the goal is GH-axis support without exogenous GH administration, allowing clearer protocol control.

Clinical Applications & Therapeutic Potential

• GHRH–GH axis activation: Enhanced endogenous GH signalling via receptor-mediated stimulation, supporting endocrine adaptation studies.
• Visceral adiposity endpoints: Reductions in visceral fat–related markers with concurrent preservation of lean-mass endpoints.
• Metabolic profile modulation: Improved metabolic marker patterns (e.g. lipid and glucose regulation endpoints) observed in structured protocols.
• Body composition optimisation: Favourable recomposition dynamics with improved fat-to-lean ratio markers over time (context-dependent).

Composition & Formulation

• Peptide content: 5 mg Sermorelin acetate
• Vehicle: Proprietary pH-balanced buffer solution
• Delivery system: Pre-filled, multi-dose, closed-system pen
• Total volume: 3 mL
• Purity: ≥99% by HPLC/MS